Most Read Articles
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.

Dementia ups risk of readmission in elderly

05 Mar 2018
The transition to the new nursing home can be very challenging for the elderly, especially for older adults with dementia or Alzheimer’s.

In elderly adults, the risk of hospital readmission associated with dementia appears to vary with the primary diagnosis, a recent study has shown.

Researchers performed a retrospective cohort study on 1,834,378 elderly adults who were discharged after receiving care for 30 of the most common diagnoses in Japan. The overall prevalence of dementia was 14.7 percent (n=269,951) and was highest in those with aspiration pneumonia (69.4 percent).

Those with dementia had significantly higher risks of hospital readmission than those without (8.3 percent vs 4.1 percent; adjusted risk ratio [aRR], 1.46; 95 percent CI, 1.44–1.49). The relationship between the two factors varied depending on the primary diagnosis, being significant in 17 of the 30 diagnostic categories.

For instance, dementia patients with a principal diagnosis of acute myocardial infarction (aRR, 1.19; 1.01–1.39), angina pectoris (aRR, 1.22; 1.09–1.36), aspiration pneumonia (aRR, 1.23; 1.16–1.30), bowel obstruction (aRR, 1.17; 1.06–1.30) and bradyarrhythmia (aRR, 1.30; 1.12–1.51) had significantly higher risks of readmission within 30 days.

Other primary diagnoses that significantly elevated the risk of 30-day readmissions included rectal cancer (aRR, 1.27; 1.07–1.51), lung cancer (aRR, 1.15; 1.06–1.26), type 2 diabetes (aRR, 1.25; 1.09–1.44), heart failure (aRR, 1.21; 1.15–1.27) and hip fractures (aRR, 1.46; 1.28–1.68).

“Healthcare providers could enforce interventions to minimize readmission by focusing on comorbid conditions in individuals with dementia and specific primary diagnoses that increase their risk of readmission,” said researchers.

Editor's Recommendations
Most Read Articles
Elvira Manzano, 29 May 2018
Repeat doses of the intrathecal antisense oligonucleotide nusinersen in children with infantile-onset spinal muscular atrophy (SMA) continue to demonstrate safety, according to  early data from the phase III SHINE extension study, bringing considerable hope to the SMA community.
Audrey Abella, 29 Aug 2018
The combination of the alkylating nitrosourea compound lomustine and the monoclonal antibody bevacizumab prolonged progression-free survival (PFS) in patients with progressive glioblastoma compared with either drug alone, a meta-analysis has shown.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
29 Aug 2018
The risk of traumatic brain injury (TBI) is elevated in young people with attention-deficit/hyperactivity disorder (ADHD), though long-term ADHD medication can reduce this risk, a recent study has found.